Breast Cancer Clinical Trial
Official title:
The CAROLE (CArdiac Related Oncologic Late Effects) Study
CAROLE seeks to evaluate the relationship between chest Radiation Therapy and coronary artery
disease.
The purpose of CAROLE is to check the heart health of women who received breast cancer
treatments in the past and protect them from future heart disease.
Background: Within the United States, there are an estimated 3.1 million women alive who have
been diagnosed with invasive breast cancer, and approximately 56% of them have received
radiation. Worldwide, there are 1.4 million diagnosed annually and, in 2012, it was the most
commonly diagnosed cancer in women. As patients continue to live longer, cardiac dose-related
toxicity has become an issue which impacts millions globally. Guidelines are sorely needed
for this large at-risk population of women.
Purpose: Radiation therapy to the chest has known cardiac late effects including coronary
artery disease, fibrosis, and valvular dysfunction. Unfortunately, there is no clear evidence
on which radiation doses to cardiac structures cause these late toxicities. As a result,
these effects are often under-recognized until after patients have become symptomatic. More
than half of breast cancer patients are treated with radiation, and many receive incidental
cardiac irradiation. Many of these women also receive systemic therapy which may pose
additional cardiac risks. The investigators data will help to establish baseline rates of
pre-clinical and clinical disease, which can be used to inform preventative guidelines that
are critically needed in this at-risk population. Additionally, the investigators data will
provide a better definition of the radiation dose-relationship associated with cardiac
toxicity so that it will be possible to predict more accurately who is at elevated risk for
iatrogenic cardiac disease.
Research Plan: This study will identify and evaluate 200 breast cancer patients treated at
the investigators institution (>6 years prior) who are at risk for treatment-related cardiac
toxicity. All patients enrolled in the study will receive echocardiograms (echo),
electrocardiograms (EKGs), and coronary calcium (CAC) CT scans in order to comprehensively
evaluate for pre-clinical and clinical cardiac disease. Patients identified as having cardiac
disease during testing will be offered referral to a cardiologist. Patients who received
non-radiation treatments (chemotherapy, hormonal therapy, and/or surgery) will be compared to
radiated patients to establish baseline rates of preclinical and clinical disease. Patients
who received cardiotoxic systemic therapy (doxorubicin, trastuzumab, etc.) will also be
evaluated in subgroup analysis. Among radiation patients, this study proposes a novel method
of risk assessment, which is, to utilize a patient's stored treatment plan (from 2004-2011)
and fuse it with patients current cardiac imaging to delineate an accurate dose relationship
associated with clinical and pre-clinical disease. This is further described in the specific
aims below:
Specific Aim 1: Identify baseline levels of clinical and pre-clinical disease in breast
cancer patients.
Aim 1.1: Delineate the group of patients diagnosed and treated for breast cancer between
2004-2011, enroll health system patients with recent follow up (within 3 years).
Aim 1.2: Perform non-invasive cardiac testing (EKG, echo, CAC CT scans). Aim 1.3: Establish
rates of pre-clinical and clinical disease based on pre-determined criteria.
Specific Aim 2: Create an accurate dosimetric assessment of dose to cardiac structures.
Aim 1.1: Among study patients who received radiation treatment for breast cancer, obtain
stored planning CT simulation scans.
Aim 1.2: Upload CT simulation scans with dosimetric information and delineate cardiac
structures at risk in order to ensure accurate and reproducible target delineation.
Aim 1.3: Fuse the CAC CT scan with the CT simulation scan to accurately assess for dose
correlation between coronary calcium with the dose received.
Aim 1.4: Create a dose-relationship model for the heart and cardiac structures.
Specific Aim 3: Incorporate dosimetric cardiac risk information into the investigators
institution's clinical practice, publish data, and establish updated cardiac guidelines for
women who have received radiation for breast cancer.
The long-term goal of the project is to elucidate specific treatment and radiation
dose-related risks, which will then be used to inform follow-up recommendations and
guidelines. This project will impact the way investigators describe expected cardiac risk to
patients, the way the investigators recommend follow up care, and potentially, the way the
investigators prescribe treatment. At present, all patients receiving radiation for breast
cancer are informed that there is a risk of cardiac late effects, however, no specific
cardiac imaging or intervention is recommended other than routine medical follow up. There is
little distinction given to the side of the cancer, a patient's individual anatomy, or the
projected dose to the anterior heart and cardiac structures. This project will allow
physicians to provide a more accurate risk profile regarding future risk of cardiac
morbidity. If the study reveals a very high rate of pre-clinical atherosclerotic disease, it
also may prompt more routine CAC CT screening.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |